



BANCA IFIGEST June 24th, 2011

# **Company Presentation**



### **Disclaimer**

Certain statements in this slide show, including those addressing the Company's beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward-looking statements. Forward-looking statements involve known or unknown risks, including general economic and business conditions, and conditions in the industry we operate and may be affected should our assumptions turn out to be inaccurate. Consequently, no forward-looking statement can be guaranteed and actual future results, performance, or achievements may vary materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation about the contents nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof.







- 2. EL.EN. GROUP
- 3. 2010 FINANCIAL RESULTS
- 4. Q1-2011 FINANCIAL RESULTS
- **5**. **2011 GUIDANCE**







# **The Global Laser Market**








## **LASER**

#### Light Amplification Stimulated by Emission of Radiation

#### **LASER Sources**

(Laser beam generator)




#### **LASER Systems**

(Manage laser beam energy to perform several applications)



## The Laser Market - Total: \$6.37 Billion



Industrial Processing \$ 2,2 B


Medical and Aesthetic \$ 0,45 B



### **El.En.: Trademarks and Markets**



### The MEDICAL Laser Market




Medical w\o diagnostic (Therapeutic) expected to grow to \$3,7B in 2014

El.En. medical revenues (FY2010) are 65% of consolidated sales



### The AESTHETIC Laser Market



- 1) Aesthetic products market (including cosmetics products) is expected to grow by 12.3% @ \$6.8 B
- 2) The skin tightening and body shaping systems market is expected to grow at the same rate, however average product prices are much higher in this segment.

Lumenis (Aesth)			
Cynosure (CYNO)(*)	2008	2009	2010
Cutera (CUTR)(*)	2000	2003	2010
Palomar (PMTI)(*)	\$ 860M	\$618M	\$683M
Syneron (ELOS) (*)			
Solta Medical (SLTM) (*)		-28%	+10%
El.En. (aesth w/o Cyno) (*)			



Source: Medical Insight Inc

(\*) Listed campanies

# The AESTHETIC Laser Market Shares

Revenues	in	\$	M
----------	----	----	---


El.En. Aesthetic/Medical Cynosure	2008 \$ 97.4 \$ 139.0	2009 \$ 72.8 \$ 72.5	2010 \$ 89.9 \$ 81.5
Peer group Total	\$ 860.7	\$ 617.7	\$ 683.7
% El.En.	11.3%	11.8%	13.1%
% Cyno	16.2%	11.7%	11.9%
% El.En. Group (*)	27.5%	23.5%	25.1%



## The INDUSTRIAL Laser Market

Laser Sources Market

Revenues (\$M)



#### Laser Systems Manufacturers Revenues (\$M)

	2008	2009	2010
Rofin Sinar	\$575	\$349	\$423
IPG	\$229	\$185	\$299
Coherent	\$599	\$435	\$605
Prima Industrie	\$477	\$300	\$325
Trumpf AG	\$2.161	\$1.742	\$2.174(*)
Total	\$4.041	\$3.011	\$3.826
% YoY Change		-25,5%	27,0%
El.En. (industrial)	\$43	\$30	\$44



Source: Laser focus World

(\*) Estimated

## **Strategic Strengths**

Multidisciplinary and multifacility R&D activity: sources, systems, applications.

Covering both Medical and Industrial laser markets

#### **Industrial**

✓ Combine High tech laser source development with flexible production facilities in high growth areas

#### Medical

- ✓ Maximize market penetration by multi brand approach
- ✓ Open new markets by developing new applications
- ✓ Leverage worldwide distribution











# El.En. Group









## **Group Overview**

#### High -Tech Industrial Group

Develops, manufactures and distributes laser sources and laser systems for medical and industrial applications

Know-how based on stratification of 30 years of multidisciplinary experience


2010 Consolidated Revenues of €190 mln, up 27% YoY

969 employees

Global positioning



# Yearly Consolidated Revenues and EBIT





## **R&D Activity**

Clinical trials and validations of new therapeutic laser treatments and research on new applications of laser-tissue interaction

Laser systems for regenerative medicine

Laser and ultrasound combination systems for minimally invasive surgery

Development of new cutting edge CO<sub>2</sub> platform

High power surgical lasers

Integrated laser systems for skin ulcers treatment

Home use systems: Unilever project

Further improvements in laser lipolysis and cellulite treatment systems

Cutting and welding applications for 5 axes laser systems



# R&D expenses as of Dec. 31st, 2010

	31/12/09	31/12/10	Var.%
R&D expenses	11,381	12,333	8.4%
Percentage on group revenues	8%	6%	
Grants	1,138	1,018	-10.5%

- √ 100 Researchers
- ✓ 5 R&D labs:

Florence, Milan, Naples, Jena, Boston





## Medical/Aesthetic

#### Aesthetic

Hair Removal

Vascular Lesions

Skin Rejuvenation

**Pigmented Lesions** 

**Treatment of Cellulite** 

Acne

Tattoo Removal

Anti - Aging

LaserBody Sculpting

Removal of Unwanted Fat

















#### Medical

**ENT** 

Gynaechology

Urology

Endovascular

Onchology

Dermatology

Psoriasis and Vitiligo

Dentistry

Therapy





## **Cynosure**

		o processing
2002	70 % Acquisition	share price \$3,5
2003-2004	Turnaround	
2005	Nasdaq IPO, holding down to 35%	share price \$ 15
2007	Stock sale, holding down to 23%	share price \$ 29
Control and	consolidation allowed by a stat	tutory clause
	2003-2004 2005 2007	<ul> <li>2003-2004 Turnaround</li> <li>2005 Nasdaq IPO, holding down to 35%</li> <li>2007 Stock sale,</li> </ul>





# **Cynosure**




#### Strategic cooperation

R&D	Smartlipo MPX – Triplex - Cellulaze			
Distribution	Smartlipo - Fractional CO <sub>2</sub> – Tattoo Removal			
	2008	2009	2010	
Sales of ex Cyno El.En. group to Cynosure (Euro 000)	12,560	4,369	4,163	
% on ex Cyno Aesthetic sales	16.80%	7.80%	6.00%	







## **Cynosure**











# **2010 Financial Results**





# Consolidated P&L - FY2010

bin.		31/12/09	31/12/10	Var.%
	Revenues	149,111 100.0	0% 189,797 10	00.0% 27.3%
	Gross margin	79,287 <i>53.2</i>	2% 100,448 5	52.9% 26.7%
	EBITDA	(4,026) -2.2	7% 14,297	7.5%
	EBIT	(12,598) <i>-8.4</i>	4% 5,422	2.9%
Ind	come before taxes	(12,331) -8.3	3% 4,689	2.5%
	Net Income (Loss)	(5,258) <i>-3.</i> 5	5% 1,268	0.7%

	31/12/09	31/12/10	
Net financial position	68,891	74,900	



# **Consolidated BS – FY2010**

	31/12/09	31/12/10	Var.
Goodwill	5,881	6,089	208
Tangible and Intangible assets	30,939	29,979	-960
Other non current assets	9,385	13,858	4,472
Total non current assets	46,205	49,925	3,720
Inventory	50,531	55,650	5,119
Accounts receivables	36,573	46,714	10,142
Other short-term receivables	12,964	13,619	655
Accounts payables	-25,136	-35,138	-10,001
Other short-term payables	-18,497	-24,951	-6,454
Net Working Capital	56,434	55,895	-539
Other non current liabilities	-8,167	-8,996	-828
Net Invested Capital	94,472	96,825	2,352
Parent stockholders' equity	90,247	94,139	3,892
Minority interests in			
consolidated subsidiaries	73,117	77,585	4,468
Total equity (1)	163,364	171,724	8,361
Net Financial Position (2)	68,891	74,900	6,008

1) Forex effect: +7.5 mln €

2) Forex effect: +4.7 mln €



# Consolidated P&L - FY2010 (w/o Cynosure)

Table 26	31/12/09		31/12/10		Var.%
Revenues	101,764	100.0%	132,566	100.0%	30.3%
Gross margin	50,325	49.5%	67,076	50.6%	33.3%
EBITDA	2,282	2.2%	13,327	10.1%	484.1%
EBIT	(1,454)	-1.4%	8,361	6.3%	
Income before taxes	(2,016)	-2.0%	7,697	5.8%	
Net Income (Loss)	(3,071)	-3.0%	2,200	1.7%	
	31/12/09		31/12/10		
Net financial position	8,830		10,042		



## El.En. – Revenues breakdown by business



#### ■ Industrial


Cutting
Marking
Laser sources

#### Service

Medical Industrial

#### Medical

Aesthetic
Surgical CO<sub>2</sub>
Physiotherapy
Dental



December 31st 2009

December 31st 2010

Cynosure

Medical

Aesthetic Service Q1-2011: +9%



## El.En. - Medical and Aesthetic Sector



Industrial

#### Medical

Service

Accessories


Other Medical Lasers

Dental

■ Aesthetic

Physiotherapy

■ Surgical CO2



December 31st 2009

December 31st 2010

Q1-2011: -6%

Cynosure

Medical

Aesthetic Service



### **El.En. – Industrial Sector**



#### Industrial

Other

Brazil


■ China

Europe

Italy

Service

Medical



December 31st 2009

December 31st 2010

Q1-2011: +56%

Cynosure

Medical

Aesthetic





# Q1 - 2011 Financial Results





# Consolidated P&L Q1-2011

	31/03/10		31/03/11		Var.%
	unaudited		unaudited		
Revenues	41,061	100.0%	45,338	100.0%	10.4%
<b>Gross margin</b>	21,927	53.4%	24,640	54.3%	12.4%
EBITDA	1,377	3.4%	2,130	4.7%	54.7%
EBIT	(492)	-1.2%	(470)	-1.0%	-4.5%
Income before taxes	(433)	-1.1%	(1,308)	-2.9%	202.0%
	31/12/10		31/03/11		
Net financial position	74,900		61,159		



# Consolidated P&L Q1-2011 (w/o Cynosure)

	31/03/10		31/03/11		Var.%
	unaudited	unaudited			
Revenues	28,397	100.0%	30,885	100.0%	8.8%
Gross margin	14,220	50.1%	16,228	52.5%	14.1%
EBITDA	1,695	6.0%	2,401	7.8%	41.7%
EBIT	971	3.4%	1,009	3.3%	3.9%
Income before taxes	1,114	3.9%	(6)	0.0%	
	31/12/10		31/03/11		
Net financial position	10,042		3,639		





# **2011 Guidance**









### 2010 - Out of the downturn

#### Rapidly

- ✓ Industrial laser systems in China and Brazil
- ✓ Surgical laser systems by Quanta System
- ✓ Aesthetic laser systems in Europe and Far East

#### Slowly

✓ Aesthetic laser systems in US and Spain

#### ...and investing

- ✓ Distribution in the US for Deka Dental and Medical
- ✓ Distribution in Italy for the SPA market



## 2011 forecast - El.En. stand alone

2010 2011 *Var.*Sales 133 Mln 146 Mln 10%


EBIT % 6.3%

EBIT% improvement expected



# El.En. and Cynosure stock performance





#### Cynosure





#### El.En. SPA

Enrico ROMAGNOLI

Investor Relations Director
tel. +39 055-8826807
E-mail: finance@elen.it

#### POLYTEMS HIR SRL

Bianca FERSINI MASTELLONI

Financial Communication & Press office

Tel. +39 06-6797849 / +39 06-69923324

E-mail: b.fersini@polytemshir.it

